secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001493152-26-021706
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack submits IDE to FDA for US clinical study of implantable CBGM
-----------------------------------------------------------------------

- Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.
- CBGM is designed for 3-year sensor longevity, blood-based accuracy, and no on-body wearable component.
- Company plans to proceed with US clinical study following FDA review and approval of the IDE.
- IDE submission follows years of preclinical evaluation and iterative engineering; data support advancing to clinical evaluation.
- CEO Paul Goode stated the submission reflects progress toward offering a discreet, accurate CGM option for diabetes patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226021706/0001493152-26-021706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226021706/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer